Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Regeneron Pharmaceuticals Inc (REGN) vs United States Oil ETF (USO) Price & Performance

Regeneron Pharmaceuticals IncTrade
United States Oil ETFTrade

Price performance (Past 24H)

Key statistics

Regeneron Pharmaceuticals Inc vs United States Oil ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while United States Oil ETF trades at $148.2. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while United States Oil ETF pays none. Which is the better fit depends on your goals.

REGNUSO
Market Cap
$83.43B
Sector
Health
52-Week High
$852.03$152.96
52-Week Low
$555.51$66.17
Enterprise Value
$78.14B
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.

United States Oil ETF

USO is trading at $146.03, up 2.87% amid strong bullish momentum driven by escalating Middle East tensions pushing oil prices higher. The technical picture shows overwhelming bullish signals with moving averages strongly supporting upward momentum, though oscillators indicate potential overbought conditions. Recent news highlights supply disruptions in the Strait of Hormuz driving Brent crude above $100 per barrel, creating favorable conditions for energy sector performance.

The outlook remains positive as geopolitical tensions continue to support oil prices, though elevated RSI levels suggest near-term consolidation risk. Key resistance at $147-$150 presents the next challenge, while support at $144-$142 provides downside protection. Energy sector strength appears sustainable given ongoing supply constraints and OPEC+ production discipline.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN

About United States Oil ETF

This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.

Read more on USO